Zydus Cadila’s COVID vaccine ZyCoV-D gets approval for Emergency Use Authorisation
With EUA, ZyCoV-D has also become the first vaccine to be administered to those in the age group of 12-18 years in the country
Author
Covishield’s booster dose desirable, says Cyrus Poonawalla
Since there was a shortage of the vaccine, the Modi government changed it to three months, but a two-month gap is ideal,"…
Bharat Biotech’s intra-nasal COVID vaccine gets DCGI nod for phase-II and -III trials
Phase-I clinical trial has been completed in age groups ranging from 18 to 60 years
USFDA gives nod to Cipla’s generic product
According to IQVIA (IMS Health), Durezol had US sales of around $106 million for the 12-month period ending June 2021
Cadila Healthcare’s net profit rises 29 per cent in Q1
Consolidated total revenue from operations stood at Rs 4,025.4 crores for the quarter under consideration against Rs 3,514.6…
CDSCO approves study on mixing of Covaxin and Covishield doses
"The aim of the study is to assess the feasibility on whether a person can be given two different vaccine shots -- one each of…
Centre approves Bharat Biotech’s Ankleshwar plant for Covaxin production: Mandaviya
In May this year, Bharat Biotech had announced that it plans to produce an additional 200 million doses of Covaxin at its…
AstraZeneca India’s Q1 net profit declines 45 per cent
Revenue from operations stood at Rs 175.40 crores for the quarter under consideration. It was Rs 193.57 crores for the same period…
Strides Pharma Science to acquire Endo’s manufacturing facility in US
Strides said the facility at Chestnut Ridge, New York has an annual capacity of two billion units across semi-solids, liquids and…
Cipla Q1 net profit rises 25 per cent to Rs 709.92 crores
The company had posted a net profit of Rs 566.04 crores in the corresponding period of the previous fiscal, Cipla said in a filing…